Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Galera Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Galera Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Galera Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $1,388,000, a 76% increase year-over-year.
  • Galera Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $19,160,000, a 68% increase from 2023.
  • Galera Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $59,082,000, a 5.2% increase from 2022.
  • Galera Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $62,292,000, a 23% increase from 2021.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Galera Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,388,000 +$4,396,000 +76% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $5,784,000 +$9,289,000 +62% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2023 $15,073,000 01 Jul 2023 30 Sep 2023 10-Q 13 Dec 2024 2024 Q3
Q3 2019 $13,351,000 -$8,050,000 -152% 01 Jul 2019 30 Sep 2019 10-Q 10 Dec 2019 2019 Q3
Q3 2018 $5,301,000 01 Jul 2018 30 Sep 2018 10-Q 10 Dec 2019 2019 Q3

Galera Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $19,160,000 +$39,922,000 +68% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $59,082,000 +$3,210,000 +5.2% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $62,292,000 +$18,242,000 +23% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $80,534,000 -$6,300,000 -8.5% 01 Jan 2021 31 Dec 2021 10-K 08 Mar 2023 2022 FY
2020 $74,234,000 -$22,295,000 -43% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $51,939,000 -$28,040,000 -117% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $23,899,000 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.